Markets

Sector Update: Healthcare; Valeant Unit Wins U.S. FDA Approval for Jublia Nail Infection Treatment

Healthcare stocks were generally lower in afternoon trading, with the S&P/TSX Healthcare index slipping 0.4%.

Valeant Pharmaceuticals (VRX.TO): -0.7%

Tekmira Pharmaceuticals (TKM.TO): +8.4%

Catamaran (CCT.TO): -0.5%

Oncolytics Biotech (ONC.TO): +3.5%

Cardiome Pharma (COM.TO): -0.4%

In corporate news, Valeant Pharmaceuticals Monday said its Valeant Pharmaceuticals North America subsidiary has received U.S. FDA approval for Jublia, the first of its kind for the treatment of nail infection (onychomycosis). The drug maker said Jublia was acquired through the purchase of Dow Pharmaceutical Sciences in 2008. It has advanced Jublia from pre-IND stage through clinical phases 1, 2, and 3 since then.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Commodities

Latest Markets Videos

    MTNewswires

    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More